Rechallenge with gefitinib following severe drug-induced hepatotoxicity in a patient with advanced non-small cell lung cancer: A case report and literature review

Gefitinib has come to be the most widely used epidermal growth factor receptor-tyrosine kinase inhibitor in the treatment of advanced non-small cell lung cancer (NSCLC) in Asian patients. Common side effects include mild to moderate skin rash and diarrhea, however, drug-induced liver injury of varyi...

Descripción completa

Detalles Bibliográficos
Autores principales: CHEN, XUEQIN, PAN, YUELONG, ZHANG, SHIRONG, CHEN, DADONG, YANG, SHAOYU, LI, XIN, MA, SHENGLIN
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2014
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3919904/
https://www.ncbi.nlm.nih.gov/pubmed/24527096
http://dx.doi.org/10.3892/ol.2013.1756

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3919904/
https://www.ncbi.nlm.nih.gov/pubmed/24527096
http://dx.doi.org/10.3892/ol.2013.1756

Ejemplares similares